Antiangiogenic treatment improves survival in animal model of ovarian cancer

Epithelial ovarian cancer is the most lethal cancer of the female reproductive organs, with more than 200,000 new cases and more than 125,000 deaths each year worldwide. Now new research in an animal model finds that a novel combination therapy, which couples low-dose chemotherapy with an antiangiogenic treatment, resulted in better survival rates compared with standard therapy. Led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and the University of Guelph, the findings show that the agent, 3TSR, not only led to tumor regression, but also improved tumor blood flow and enabled more efficient delivery of much smaller and less toxic doses of chemotherapy. Read more here.